Branebrutinib
Small moleculeexperimental
Clinical trial activity
15 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
11
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2014 (NCT02257151)
Timeline
Indications
Mechanism of action
- Tyrosine-protein kinase BTKINHIBITOR
BTK inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CC#CC(=O)N[C@H]1CCCN(c2c(F)cc(C(N)=O)c3[nH]c(C)c(C)c23)C1- Mol. weight
- 370.43 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297674 ↗
Also known as
- bms-986142
- bms-986142
- bms-986195
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05303220 | Phase 1 | Apr 8, 2022 | Bristol-Myers Squibb |
| NCT05014438 | Phase 2 | Aug 16, 2021 | Bristol-Myers Squibb |
| NCT04515628 | Phase 1 | Aug 17, 2020 | Bristol-Myers Squibb |
| NCT04186871 | Phase 2 | Dec 3, 2019 | Bristol-Myers Squibb |
| NCT03262740 | Phase 1 | Sep 11, 2017 | Bristol-Myers Squibb |
| NCT03245515 | Phase 1 | Aug 15, 2017 | Bristol-Myers Squibb |
| NCT03131973 | Phase 1 | May 13, 2017 | Bristol-Myers Squibb |
| NCT02843659 | Phase 2 | Oct 18, 2016 | Bristol-Myers Squibb |
| NCT02705989 | Phase 1 | Aug 18, 2016 | Bristol-Myers Squibb |
| NCT02880670 | Phase 1 | Aug 1, 2016 | Bristol-Myers Squibb |
| NCT02832180 | Phase 1 | May 1, 2016 | Bristol-Myers Squibb |
| NCT02762123 | Phase 1 | May 1, 2016 | Bristol-Myers Squibb |
| NCT02638948 | Phase 2 | Feb 16, 2016 | Bristol-Myers Squibb |
| NCT02456844 | Phase 1 | May 1, 2015 | Bristol-Myers Squibb, PPD |
| NCT02257151 | Phase 1 | Sep 1, 2014 | Bristol-Myers Squibb |
Showing 15 of 15 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bristol-Myers Squibb | For profit | 15 | 15 | 2 | 2014 |
| PPD | For profit | 1 | 0 | 1 | 2015 |
2 organizations
Page 1 / 1